Ishii, T., Kawazoe, A., Sasaki, A., Mishima, S., Kentaro, S., Nakamura, Y., . . . Shitara, K. (2020). Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer. Ther Adv Med Oncol.
シカゴスタイル引用形Ishii, Takahiro, et al. "Clinical and Molecular Factors for Selection of Nivolumab or Irinotecan As Third-line Treatment for Advanced Gastric Cancer." Ther Adv Med Oncol 2020.
MLA引用形式Ishii, Takahiro, et al. "Clinical and Molecular Factors for Selection of Nivolumab or Irinotecan As Third-line Treatment for Advanced Gastric Cancer." Ther Adv Med Oncol 2020.
警告: この引用は必ずしも正確ではありません.